▶ 調査レポート

世界の腫瘍壊死因子阻害剤市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Tumor Necrosis Factor Inhibitors Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の腫瘍壊死因子阻害剤市場 2021:企業別、地域別、種類・用途別 / Global Tumor Necrosis Factor Inhibitors Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 / GIR-107A14793資料のイメージです。• レポートコード:GIR-107A14793
• 出版社/出版日:GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、101ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、腫瘍壊死因子阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。腫瘍壊死因子阻害剤の種類別市場規模(フミラ、エンブレル、レミケード、その他)、用途別市場規模(アルツハイマー病、パーキンソン病、虚血性脳卒中、多発性硬化症、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・腫瘍壊死因子阻害剤の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):EPIRUS Biopharmaceuticals、Bionovis、CASI Pharmaceuticals、Janssen Biotech、Momenta Pharmaceuticals、GlaxoSmithKline、HanAll Biopharma、Intas Pharmaceuticals、LEO Pharma、Dexa Medica、LG Life Sciences、MedImmune
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:フミラ、エンブレル、レミケード、その他
・用途別分析2016年-2026年:アルツハイマー病、パーキンソン病、虚血性脳卒中、多発性硬化症、その他
・腫瘍壊死因子阻害剤の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・腫瘍壊死因子阻害剤のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・腫瘍壊死因子阻害剤のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・腫瘍壊死因子阻害剤の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・腫瘍壊死因子阻害剤の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Tumor Necrosis Factor Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Tumor Necrosis Factor Inhibitors size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Tumor Necrosis Factor Inhibitors market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Tumor Necrosis Factor Inhibitors market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Humira
Enbrel
Remicade
Others

Market segment by Application can be divided into
Alzheimer’s Diseases
Parkinson’s Diseases
Ischemic Stroke
Multiple Sclerosis
Others

The key market players for global Tumor Necrosis Factor Inhibitors market are listed below:
EPIRUS Biopharmaceuticals
Bionovis
CASI Pharmaceuticals
Janssen Biotech
Momenta Pharmaceuticals
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
Dexa Medica
LG Life Sciences
MedImmune

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Tumor Necrosis Factor Inhibitors product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Tumor Necrosis Factor Inhibitors, with price, sales, revenue and global market share of Tumor Necrosis Factor Inhibitors from 2019 to 2021.
Chapter 3, the Tumor Necrosis Factor Inhibitors competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tumor Necrosis Factor Inhibitors breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Tumor Necrosis Factor Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Tumor Necrosis Factor Inhibitors sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Tumor Necrosis Factor Inhibitors Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Tumor Necrosis Factor Inhibitors Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Humira
1.2.3 Enbrel
1.2.4 Remicade
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Tumor Necrosis Factor Inhibitors Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Alzheimer’s Diseases
1.3.3 Parkinson’s Diseases
1.3.4 Ischemic Stroke
1.3.5 Multiple Sclerosis
1.3.6 Others
1.4 Global Tumor Necrosis Factor Inhibitors Market Size & Forecast
1.4.1 Global Tumor Necrosis Factor Inhibitors Sales in Value (2016-2026))
1.4.2 Global Tumor Necrosis Factor Inhibitors Sales in Volume (2016-2026)
1.4.3 Global Tumor Necrosis Factor Inhibitors Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Tumor Necrosis Factor Inhibitors Production Capacity Analysis
1.5.1 Global Tumor Necrosis Factor Inhibitors Total Production Capacity (2016-2026)
1.5.2 Global Tumor Necrosis Factor Inhibitors Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Tumor Necrosis Factor Inhibitors Market Drivers
1.6.2 Tumor Necrosis Factor Inhibitors Market Restraints
1.6.3 Tumor Necrosis Factor Inhibitors Trends Analysis
2 Manufacturers Profiles
2.1 EPIRUS Biopharmaceuticals
2.1.1 EPIRUS Biopharmaceuticals Details
2.1.2 EPIRUS Biopharmaceuticals Major Business
2.1.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product and Services
2.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Bionovis
2.2.1 Bionovis Details
2.2.2 Bionovis Major Business
2.2.3 Bionovis Tumor Necrosis Factor Inhibitors Product and Services
2.2.4 Bionovis Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 CASI Pharmaceuticals
2.3.1 CASI Pharmaceuticals Details
2.3.2 CASI Pharmaceuticals Major Business
2.3.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product and Services
2.3.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Janssen Biotech
2.4.1 Janssen Biotech Details
2.4.2 Janssen Biotech Major Business
2.4.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Product and Services
2.4.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Momenta Pharmaceuticals
2.5.1 Momenta Pharmaceuticals Details
2.5.2 Momenta Pharmaceuticals Major Business
2.5.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product and Services
2.5.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business
2.6.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product and Services
2.6.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 HanAll Biopharma
2.7.1 HanAll Biopharma Details
2.7.2 HanAll Biopharma Major Business
2.7.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Product and Services
2.7.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Intas Pharmaceuticals
2.8.1 Intas Pharmaceuticals Details
2.8.2 Intas Pharmaceuticals Major Business
2.8.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product and Services
2.8.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 LEO Pharma
2.9.1 LEO Pharma Details
2.9.2 LEO Pharma Major Business
2.9.3 LEO Pharma Tumor Necrosis Factor Inhibitors Product and Services
2.9.4 LEO Pharma Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Dexa Medica
2.10.1 Dexa Medica Details
2.10.2 Dexa Medica Major Business
2.10.3 Dexa Medica Tumor Necrosis Factor Inhibitors Product and Services
2.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 LG Life Sciences
2.11.1 LG Life Sciences Details
2.11.2 LG Life Sciences Major Business
2.11.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Product and Services
2.11.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 MedImmune
2.12.1 MedImmune Details
2.12.2 MedImmune Major Business
2.12.3 MedImmune Tumor Necrosis Factor Inhibitors Product and Services
2.12.4 MedImmune Tumor Necrosis Factor Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Tumor Necrosis Factor Inhibitors Sales by Manufacturer
3.1 Global Tumor Necrosis Factor Inhibitors Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Tumor Necrosis Factor Inhibitors
3.4 Market Concentration Rate
3.4.1 Top 3 Tumor Necrosis Factor Inhibitors Manufacturer Market Share
3.4.2 Top 6 Tumor Necrosis Factor Inhibitors Manufacturer Market Share
3.5 Global Tumor Necrosis Factor Inhibitors Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Tumor Necrosis Factor Inhibitors Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Tumor Necrosis Factor Inhibitors Market Size by Region
4.1.1 Global Tumor Necrosis Factor Inhibitors Sales in Volume by Region (2016-2026)
4.1.2 Global Tumor Necrosis Factor Inhibitors Revenue by Region (2016-2026)
4.2 North America Tumor Necrosis Factor Inhibitors Revenue (2016-2026)
4.3 Europe Tumor Necrosis Factor Inhibitors Revenue (2016-2026)
4.4 Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue (2016-2026)
4.5 South America Tumor Necrosis Factor Inhibitors Revenue (2016-2026)
4.6 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Tumor Necrosis Factor Inhibitors Sales in Volume by Type (2016-2026)
5.2 Global Tumor Necrosis Factor Inhibitors Revenue by Type (2016-2026)
5.3 Global Tumor Necrosis Factor Inhibitors Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Tumor Necrosis Factor Inhibitors Sales in Volume by Application (2016-2026)
6.2 Global Tumor Necrosis Factor Inhibitors Revenue by Application (2016-2026)
6.3 Global Tumor Necrosis Factor Inhibitors Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Tumor Necrosis Factor Inhibitors Sales by Type (2016-2026)
7.2 North America Tumor Necrosis Factor Inhibitors Sales by Application (2016-2026)
7.3 North America Tumor Necrosis Factor Inhibitors Market Size by Country
7.3.1 North America Tumor Necrosis Factor Inhibitors Sales in Volume by Country (2016-2026)
7.3.2 North America Tumor Necrosis Factor Inhibitors Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Tumor Necrosis Factor Inhibitors Sales by Type (2016-2026)
8.2 Europe Tumor Necrosis Factor Inhibitors Sales by Application (2016-2026)
8.3 Europe Tumor Necrosis Factor Inhibitors Market Size by Country
8.3.1 Europe Tumor Necrosis Factor Inhibitors Sales in Volume by Country (2016-2026)
8.3.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Sales by Type (2016-2026)
9.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Sales by Application (2016-2026)
9.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Market Size by Region
9.3.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Tumor Necrosis Factor Inhibitors Sales by Type (2016-2026)
10.2 South America Tumor Necrosis Factor Inhibitors Sales by Application (2016-2026)
10.3 South America Tumor Necrosis Factor Inhibitors Market Size by Country
10.3.1 South America Tumor Necrosis Factor Inhibitors Sales in Volume by Country (2016-2026)
10.3.2 South America Tumor Necrosis Factor Inhibitors Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Type (2016-2026)
11.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Application (2016-2026)
11.3 Middle East & Africa Tumor Necrosis Factor Inhibitors Market Size by Country
11.3.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Tumor Necrosis Factor Inhibitors Typical Distributors
12.3 Tumor Necrosis Factor Inhibitors Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Tumor Necrosis Factor Inhibitors Revenue by Type, (USD Million), 2021-2026
Table 2. Global Tumor Necrosis Factor Inhibitors Revenue by Application, (USD Million), 2021-2026
Table 3. EPIRUS Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. EPIRUS Biopharmaceuticals Major Business
Table 5. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product and Services
Table 6. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Bionovis Basic Information, Manufacturing Base and Competitors
Table 8. Bionovis Major Business
Table 9. Bionovis Tumor Necrosis Factor Inhibitors Product and Services
Table 10. Bionovis Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. CASI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 12. CASI Pharmaceuticals Major Business
Table 13. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product and Services
Table 14. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table 16. Janssen Biotech Major Business
Table 17. Janssen Biotech Tumor Necrosis Factor Inhibitors Product and Services
Table 18. Janssen Biotech Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Momenta Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 20. Momenta Pharmaceuticals Major Business
Table 21. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product and Services
Table 22. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 24. GlaxoSmithKline Major Business
Table 25. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product and Services
Table 26. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. HanAll Biopharma Basic Information, Manufacturing Base and Competitors
Table 28. HanAll Biopharma Major Business
Table 29. HanAll Biopharma Tumor Necrosis Factor Inhibitors Product and Services
Table 30. HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Intas Pharmaceuticals Major Business
Table 33. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product and Services
Table 34. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. LEO Pharma Basic Information, Manufacturing Base and Competitors
Table 36. LEO Pharma Major Business
Table 37. LEO Pharma Tumor Necrosis Factor Inhibitors Product and Services
Table 38. LEO Pharma Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Dexa Medica Basic Information, Manufacturing Base and Competitors
Table 40. Dexa Medica Major Business
Table 41. Dexa Medica Tumor Necrosis Factor Inhibitors Product and Services
Table 42. Dexa Medica Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. LG Life Sciences Basic Information, Manufacturing Base and Competitors
Table 44. LG Life Sciences Major Business
Table 45. LG Life Sciences Tumor Necrosis Factor Inhibitors Product and Services
Table 46. LG Life Sciences Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. MedImmune Basic Information, Manufacturing Base and Competitors
Table 48. MedImmune Major Business
Table 49. MedImmune Tumor Necrosis Factor Inhibitors Product and Services
Table 50. MedImmune Tumor Necrosis Factor Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Global Tumor Necrosis Factor Inhibitors Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 52. Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 53. Market Position of Manufacturers in Tumor Necrosis Factor Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 54. Global Tumor Necrosis Factor Inhibitors Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 55. Head Office and Tumor Necrosis Factor Inhibitors Production Site of Key Manufacturer
Table 56. Tumor Necrosis Factor Inhibitors New Entrant and Capacity Expansion Plans
Table 57. Tumor Necrosis Factor Inhibitors Mergers & Acquisitions in the Past Five Years
Table 58. Global Tumor Necrosis Factor Inhibitors Sales by Region (2016-2021e) & (K Pcs)
Table 59. Global Tumor Necrosis Factor Inhibitors Sales by Region (2021-2026) & (K Pcs)
Table 60. Global Tumor Necrosis Factor Inhibitors Revenue by Region (2016-2021e) & (USD Million)
Table 61. Global Tumor Necrosis Factor Inhibitors Revenue by Region (2021-2026) & (USD Million)
Table 62. Global Tumor Necrosis Factor Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 63. Global Tumor Necrosis Factor Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 64. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2016-2021e) & (USD Million)
Table 65. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 66. Global Tumor Necrosis Factor Inhibitors Price by Type (2016-2021e) & (USD/Pcs)
Table 67. Global Tumor Necrosis Factor Inhibitors Price by Type (2021-2026) & (USD/Pcs)
Table 68. Global Tumor Necrosis Factor Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 69. Global Tumor Necrosis Factor Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 70. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2016-2021e) & (USD Million)
Table 71. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 72. Global Tumor Necrosis Factor Inhibitors Price by Application (2016-2021e) & (USD/Pcs)
Table 73. Global Tumor Necrosis Factor Inhibitors Price by Application (2021-2026) & (USD/Pcs)
Table 74. North America Tumor Necrosis Factor Inhibitors Sales by Country (2016-2021e) & (K Pcs)
Table 75. North America Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (K Pcs)
Table 76. North America Tumor Necrosis Factor Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 77. North America Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 78. North America Tumor Necrosis Factor Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 79. North America Tumor Necrosis Factor Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 80. North America Tumor Necrosis Factor Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 81. North America Tumor Necrosis Factor Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 82. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2016-2021e) & (K Pcs)
Table 83. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (K Pcs)
Table 84. Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 85. Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 86. Europe Tumor Necrosis Factor Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 87. Europe Tumor Necrosis Factor Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 88. Europe Tumor Necrosis Factor Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 89. Europe Tumor Necrosis Factor Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 90. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales by Region (2016-2021e) & (K Pcs)
Table 91. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales by Region (2021-2026) & (K Pcs)
Table 92. Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue by Region (2016-2021e) & (USD Million)
Table 93. Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue by Region (2021-2026) & (USD Million)
Table 94. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 95. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 96. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 97. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 98. South America Tumor Necrosis Factor Inhibitors Sales by Country (2016-2021e) & (K Pcs)
Table 99. South America Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (K Pcs)
Table 100. South America Tumor Necrosis Factor Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 101. South America Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 102. South America Tumor Necrosis Factor Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 103. South America Tumor Necrosis Factor Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 104. South America Tumor Necrosis Factor Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 105. South America Tumor Necrosis Factor Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 106. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Country (2016-2021e) & (K Pcs)
Table 107. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (K Pcs)
Table 108. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 109. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 110. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 111. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 112. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 113. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 114. Direct Channel Pros & Cons
Table 115. Indirect Channel Pros & Cons
Table 116. Tumor Necrosis Factor Inhibitors Typical Distributors
Table 117. Tumor Necrosis Factor Inhibitors Typical Customers
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitors Picture
Figure 2. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type in 2020
Figure 3. Humira
Figure 4. Enbrel
Figure 5. Remicade
Figure 6. Others
Figure 7. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application in 2020
Figure 8. Alzheimer's Diseases
Figure 9. Parkinson's Diseases
Figure 10. Ischemic Stroke
Figure 11. Multiple Sclerosis
Figure 12. Others
Figure 13. Global Tumor Necrosis Factor Inhibitors Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 14. Global Tumor Necrosis Factor Inhibitors Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Tumor Necrosis Factor Inhibitors Sales (2016-2026) & (K Pcs)
Figure 16. Global Tumor Necrosis Factor Inhibitors Price by Type (2016-2026) & (USD/Pcs)
Figure 17. Global Tumor Necrosis Factor Inhibitors Production Capacity (2016-2026) & (K Pcs)
Figure 18. Global Tumor Necrosis Factor Inhibitors Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Tumor Necrosis Factor Inhibitors Market Drivers
Figure 20. Tumor Necrosis Factor Inhibitors Market Restraints
Figure 21. Tumor Necrosis Factor Inhibitors Market Trends
Figure 22. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturer in 2020
Figure 23. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Manufacturer in 2020
Figure 24. Tumor Necrosis Factor Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Tumor Necrosis Factor Inhibitors Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Tumor Necrosis Factor Inhibitors Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2016-2026)
Figure 28. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2016-2026)
Figure 29. North America Tumor Necrosis Factor Inhibitors Revenue (2016-2026) & (USD Million)
Figure 30. Europe Tumor Necrosis Factor Inhibitors Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue (2016-2026) & (USD Million)
Figure 32. South America Tumor Necrosis Factor Inhibitors Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue (2016-2026) & (USD Million)
Figure 34. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2016-2026)
Figure 35. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2016-2026)
Figure 36. Global Tumor Necrosis Factor Inhibitors Price by Type (2016-2026) & (USD/Pcs)
Figure 37. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2016-2026)
Figure 38. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2016-2026)
Figure 39. Global Tumor Necrosis Factor Inhibitors Price by Application (2016-2026) & (USD/Pcs)
Figure 40. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2016-2026)
Figure 41. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2016-2026)
Figure 42. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2016-2026)
Figure 43. North America Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2016-2026)
Figure 44. United States Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2016-2026)
Figure 48. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2016-2026)
Figure 49. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2016-2026)
Figure 50. Europe Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2016-2026)
Figure 51. Germany Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2016-2026)
Figure 60. China Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2016-2026)
Figure 67. South America Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2016-2026)
Figure 68. South America Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2016-2026)
Figure 69. South America Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Tumor Necrosis Factor Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source